Grail (NASDAQ:GRAL - Get Free Report) will be releasing its earnings data after the market closes on Tuesday, November 12th. Investors interested in registering for the company's conference call can do so using this link.
Grail (NASDAQ:GRAL - Get Free Report) last released its earnings results on Tuesday, August 13th. The company reported ($5.30) EPS for the quarter. The company had revenue of $31.97 million during the quarter.
Grail Trading Down 0.5 %
Shares of GRAL stock traded down $0.07 during trading hours on Tuesday, reaching $13.91. 363,240 shares of the company's stock were exchanged, compared to its average volume of 1,123,211. The business's 50 day simple moving average is $13.65. Grail has a 1 year low of $12.33 and a 1 year high of $23.36.
Analyst Ratings Changes
Separately, Guggenheim began coverage on Grail in a report on Thursday, October 17th. They set a "neutral" rating on the stock.
Read Our Latest Stock Analysis on GRAL
Insider Transactions at Grail
In other news, CEO Robert P. Ragusa sold 123,454 shares of the stock in a transaction dated Tuesday, October 15th. The shares were sold at an average price of $14.02, for a total transaction of $1,730,825.08. Following the completion of the transaction, the chief executive officer now directly owns 612,661 shares in the company, valued at $8,589,507.22. This represents a 0.00 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. In related news, CEO Robert P. Ragusa sold 123,454 shares of Grail stock in a transaction on Tuesday, October 15th. The shares were sold at an average price of $14.02, for a total transaction of $1,730,825.08. Following the completion of the transaction, the chief executive officer now owns 612,661 shares of the company's stock, valued at $8,589,507.22. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, major shareholder Chun R. Ding purchased 7,629 shares of the firm's stock in a transaction on Tuesday, October 1st. The stock was bought at an average cost of $13.52 per share, with a total value of $103,144.08. Following the completion of the purchase, the insider now owns 3,503,655 shares of the company's stock, valued at approximately $47,369,415.60. This represents a 0.00 % increase in their position. The disclosure for this purchase can be found here. Over the last 90 days, insiders bought 58,829 shares of company stock valued at $757,298.
Grail Company Profile
(
Get Free Report)
GRAIL, Inc, a biotechnology company, focuses on developing technologies for early cancer detection. The company develops Galleri, a screening test for asymptomatic individuals over 50 years of age; and DAC, a diagnostic aid for cancer tests to accelerate diagnostic resolution for patients for whom there is a clinical suspicion of cancer.
Featured Articles
Before you consider Grail, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Grail wasn't on the list.
While Grail currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Click the link below to learn more about using beta to protect yourself.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
